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Background-—The contribution of the lung or the plant gain (PG; ie, change in blood gases per unit change in ventilation) to
Cheyne-Stokes respiration (CSR) in heart failure has only been hypothesized by mathematical models, but never been directly
evaluated.
Methods and Results-—Twenty patients with systolic heart failure (age, 72.46.4 years; left ventricular ejection fraction,
31.55.8%), 10 with relevant CSR (24-hour apnea-hypopnea index [AHI] ≥10 events/h) and 10 without (AHI <10 events/h) at 24-
hour cardiorespiratory monitoring underwent evaluation of chemoreflex gain (CG) to hypoxia (CGO2 ) and hypercapnia (CGCO2 ) by
rebreathing technique, lung-to-finger circulation time, and PG assessment through a visual system. PG test was feasible and
reproducible (intraclass correlation coefficient, 0.98; 95% CI, 0.91–0.99); the best-fitting curve to express the PG was a hyperbola
(R2≥0.98). Patients with CSR showed increased PG, CGCO2 (but not CGO2 ), and lung-to-finger circulation time, compared with
patients without CSR (all P<0.05). PG was the only predictor of the daytime AHI (R=0.56, P=0.01) and together with the CGCO2 also
predicted the nighttime AHI (R=0.81, P=0.0003) and the 24-hour AHI (R=0.71, P=0.001). Lung-to-finger circulation time was the
only predictor of CSR cycle length (R=0.82, P=0.00006).
Conclusions-—PG is a powerful contributor of CSR and should be evaluated together with the CG and circulation time to
individualize treatments aimed at stabilizing breathing in heart failure. ( J Am Heart Assoc. 2019;8:e012419. DOI: 10.1161/
JAHA.119.012419.)
Key Words: chemoreceptor • chronic heart failure • circulation • lung • sleep apnea
C heyne-Stokes respiration (CSR) is a form of periodicbreathing characterized by alternating phases of hyper-
ventilation and central apneas, typical of severe chronic
conditions, such as congestive heart failure (HF).1 This
breathing pattern results in numerous repetitive fluctuations
in blood gases and hemodynamics,1 causes chronic sympa-
thetic overactivation,2 impedes exercise capacity,3 precipi-
tates ventricular arrhythmias,4 and increases mortality in
HF.5,6 Current treatments of CSR have rarely considered its
complex pathogenesis in HF or tried to interfere with its
pathophysiological triggers, with consequent disappointing
results of major clinical trials based on positive pressure
ventilation.7,8
In the past decades, different mathematical models have
been proposed to describe the pathophysiology of CSR.9–12
The overall accepted hypothesis is that the respiratory system
could be seen as a closed-loop system, with a certain transit
time in the feedback loop.13 The loop gain (LG) can be defined
as the ratio between the power of the response to a
disturbance/the disturbance itself. Generally, the system
reacts vigorously to each perturbation with a high LG, and
with weaker effect when the LG is low.13 The main determi-
nants of LG are the controller gain and the plant gain (PG).
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The controller within the respiratory system is represented
by the chemoreflex gain (CG; change in ventilation per unit
change in PCO2 or PO2), whereas the PG is represented by the
lungs (change in PCO2 or PO2 per unit change in ventilation). The
connection between the controller and the plant is repre-
sented by the blood circulating between the lung and the
chemoreceptors.14 If the LG is <1, the response to any
respiratory disturbance does not overshoot by more than the
size of the original disturbance, so that ventilation slowly
returns to steady state. Conversely, if LG is ≥1, any respiratory
disturbance produces a response, which is even larger, leading
to growing cycles of oscillation.13
With these premises, the chemoreflex has been thoroughly
evaluated in patients with HF and CSR.15–17 Increased CG is
associated with CSR,16,17 adrenergic overactivation,16,17 and
arrhythmias16,17 and has independent prognostic significance
in HF.18,19 However, there is extensive overlap in CG between
patients with and without CSR.15
Although a few studies have also evaluated the role of
circulation time (Ct), showing mainly an association with CSR
cycle length rather than CSR severity,20 the role of PG has
never been investigated.
We hypothesized that full evaluation of the global LG,
including the CG, the PG, and the Ct, might increase the
capability to correctly predict respiratory stability and to
design future rational and effective strategies to stabilize
breathing, on the basis of tailored pathophysiological
approaches acting on CSR triggers. Therefore, we devel-
oped a novel method for direct evaluation of PG, and we
tested it in healthy subjects and in patients with HF with
and without CSR, beyond the evaluation of both the CG and
the Ct.
Methods
The data that support the findings of this study are available
from the corresponding author on reasonable request.
Study Population
Consecutive outpatients with chronic systolic HF (left ven-
tricular ejection fraction <50%) on stable (by 3 months) and
optimal guideline-recommended medical and device treat-
ment were enrolled in the study.21 Exclusion criteria were as
follows: chronic obstructive pulmonary disease or respiratory
failure22; obstructive sleep apnea syndrome; and therapy with
drug-influencing ventilation.
The study was approved by our Institutional Review
Committee, and all subjects gave informed consent.
All patients underwent the following: 2-dimensional
echocardiography23–25; neurohormonal characterization,
including plasma norepinephrine, renin, aldosterone, and
B-type natriuretic peptides26; arterial blood gas analysis;
spirometry and diffusing lung capacity for carbon monox-
ide; 24-hour cardiorespiratory monitoring (Somte; Com-
pumedics, Abbotsford, Australia),6,27 from which the
apnea-hypopnea index (AHI), the central apnea index
(CAI), the obstructive apnea index, the minimal oxygen
saturation (SaO2), time spent with SaO2 <90%, and the
lung-to-finger Ct (LFCt) were calculated, as previously
described28,29; chemoreflex sensitivity to hypoxia (CGO2 )
and hypercapnia (CGCO2 ), by the rebreathing tech-
nique17,18,30,31 (as explained below); and PG assessment
(as explained below).
On the basis of pilot analysis (4 patients with CSR [PG
mean, 2.2 mm Hg/L per minute; SD, 0.6 mm Hg/L per
minute] and 4 patients without CSR [PG mean, 1.4 mm Hg/L
per minute; SD, 0.5 mm Hg/L per minute]) using PG as the
target variable and using a 1-sided Mann-Whitney U test
(calculated effect size of 1.45) to obtain a P<0.05 and a power
of 80%, we calculated a sample size of 7 subjects per group.
To ensure robustness of our findings, we decided to recruit 10
subjects for each group. Considering that we evaluated CSR
over the 24 hours and that the 24-hour AHI has an
independent prognostic value in HF,6 we used a threshold
of 24-hour AHI ≥10 events/h to differentiate patients with
relevant CSR (n=10; 24-hour AHI ≥10 events/h) from those
without (n=10; AHI <10 events/h) in this series. A group of 10
healthy controls matched for age, sex, body mass index, and
body surface area was also recruited and underwent PG and
CG assessment.
CG Assessment
Chemoreflex sensitivity was assessed using the rebreathing
technique, as previously explained.17,18 In summary, subjects
were examined in standardized conditions, while seated and
connected to a rebreathing circuit through a mouthpiece.
ECG, airway flow, and respiratory gases were recorded
continuously through a breath-by-breath gas analyzer (Vmax;
Clinical Perspective
What Is New?
• This is the first study to explore the contribution of the lung
or the plant gain in the genesis of central apneas in patients
with heart failure.
What Are the Clinical Implications?
• Understanding the plant gain may help to predict Cheyne-
Stokes respiration severity and to refine pathophysiological
treatments aimed at stabilizing breathing in heart failure.
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Sensormedics, CA), and SaO2 was recorded through a pulse
oximeter (SET Radical; Masimo).
A 4-minute baseline recording was performed during
spontaneous breathing. Then, the CGO2 and the CGCO2 were
performed in a random order.
In the CGO2 , an isocapnic hypoxia trial was done (from
resting SaO2 values to 70%–80%, according to individual
tolerance), with end-tidal CO2 (etCO2) kept constant through a
scrubbing circuit; the CGO2 was then expressed by the linear
regression slope between minute ventilation and SaO2.
In the CGCO2 , a progressive normoxic hypercapnic trial was
done (from resting etCO2 values until 50 mm Hg or an
increase >10 mm Hg from the basal values, according to
individual tolerance), with inspired partial pressure of oxygen
kept at the baseline value by adding oxygen to the circuit; the
CGCO2 was expressed by the linear regression slope between
minute ventilation and the end-tidal pressure of CO2.
PG Assessment
To estimate the PG, we developed a new test to guide and
monitor patient’s breath-by-breath imposed variations in
minute ventilation and consequent changes in etCO2.
It was possible to refer the etCO2 to the invasive arterial
measure, excluding from the study pulmonary diseases with
different alveolar emptying constants.
To enable subjects to change ventilation to a predeter-
mined value, the subject’s signal from the pneumotachograph
(Vmax) was monitored online by a dedicated computer,
running custom-designed software. The system was pro-
grammed to change subject’s ventilation as a percentage of
resting ventilation, increasing/decreasing tidal volume and
respiratory rate by the same proportion.
The system displayed a moving bar controlled by the
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Figure 1. Schematic representation of plant gain assessment. A, The patient/software
interface showing patient’s inspiratory bar, target tidal volume (TV), and respiratory rate
(RR) dynamic cursor. B, TV target is moved away from resting TV and RR cursor changes
velocity across the different respiratory maneuvers, to obtain a prefixed percentage change
in baseline ventilation. C, The postprocessing software interface allows us to reliably select
a 20-second plateau in the end-tidal CO2 (etCO2) signal, following imposed changes in
minute ventilation (VE).
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at a respiratory rate rhythm given by a dynamic cursor
(Figure 1A and Video S1).
The study subject was first trained to familiarize with the
software interface. After a 5-minute baseline recording to
obtain resting ventilation and etCO2, each subject was asked
to perform 5 maneuvers in random order: 2 hypoventilation
maneuvers (a 20% and 10% decrease from baseline
ventilation) and 3 hyperventilation maneuvers (a 20%, 40%,
60% increase from baseline ventilation) (Figure 1B).
Each step was maintained for at least 5 minutes, until a
plateau in etCO2 had been achieved and maintained for
≥20 seconds. Each step was separated by the following one
by 5 minutes of recovery (Figure 1B). Data were then
analyzed (Figure 1C).
Table 1. Clinical Features of Patients With HF With or Without CSR
Feature Patients With HF
Patients With HF With
24-h AHI <10 events/h
Patients With HF With
24-h AHI ≥10 events/h
Total no. 20 10 10
Age, y 72.46.4 71.47.3 73.45.6
Men 19 (95) 9 (90) 10 (100)
BMI, kg/m2 26.33.3 26.14.1 26.62.5
BSA, m2 1.970.17 1.970.18 1.980.16
Plasma creatinine, mg/dL 1.120.37 1.170.48 1.070.22
eGFR, mL/min per 1.73 m2 67.720.6 6723.5 66.518.1
Hemoglobin, g/dL 13.81.3 13.90.8 13.41.7
Ischemic/idiopathic 9/11 (45/55) 5/5 (50/50) 4/6 (40/60)
NYHA class I/II/III 6/12/2 (30/60/10) 4/5/1 (40/50/10) 2/7/1 (20/70/10)
Atrial fibrillation 11 (55) 5 (50) 6 (60)
Ejection fraction, % 31.55.8 32.96.1 30.25.5
Diastolic disfunction II–III 10 (50) 5 (50) 5 (50)
Moderate-to-severe MR 8 (40) 3 (30) 5 (50)
sPAP, mm Hg 40.410.0 41.96.4 39.212.4
FAC, % 40.19.0 36.37.4 439.5
HS-troponin T, ng/L 18.4 (10.2–26.4) 13.7 (8.7–25.3) 21.5 (16.6–31.5)
Norepinephrine, ng/L 431.5 (326.8–690.5) 400 (290.5–513.0) 561 (352.0–804.8)
Renin, lU/mL 39.1 (11.7–81.6) 42.1 (14.4–95.2) 30.4 (4.1–77.0)
Aldosterone, ng/L 82.9 (56.2–127.0) 82.3 (55.1–82.3) 92.5 (67.0–127.0)
BNP, ng/L 240.0 (142.0–659.0) 219.0 (80.0–303.0) 449.5 (164.3–824.0)
NT-proBNP, ng/L 981 (484.8–2353.5) 580 (265.0–1187.8) 1340 (772.3–3494.3)*
b Blockers 20 (100) 10 (100) 10 (100)
ACEi-ARB 14 (70) 7 (70) 7 (70)
ARNI 6 (30) 3 (30) 3 (30)
MRA 17 (85) 7 (70) 10 (100)
Furosemide 11 (55) 6 (60) 5 (50)
Digoxin 1 (5) 1 (10) 0 (0)
CRT-D 7 (35) 4 (40) 3 (30)
CRT-P 1 (5) 0 (0) 1 (10)
ICD 1 (5) 0 (0) 1 (10)
Data are given as meanSD, number (percentage), or median (interquartile range). ACEi indicates angiotensin-converting enzyme inhibitor; AHI, apnea-hypopnea index; ARB, angiotensin
receptor blocker; ARNI, angiotensin receptor/neprilysin inhibitor; BMI, body mass index; BNP, brain natriuretic peptide; BSA, body surface area; CRT-D, cardiac resynchronization therapy-
defibrillator; CRT-P, CRT-pacemaker; CSR, Cheyne-Stokes respiration; eGFR, estimated glomerular filtration rate by Modification of Diet in Renal Disease equation; FAC, fractional area
change; HF, heart failure; HS, high sensitivity; ICD, implantable cardioverter-defibrillator; MR, mitral regurgitation; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-
type natriuretic peptide; NYHA, New York Heart Association; sPAP, systolic pulmonary artery pressure.
*P<0.05 vs patients with HF with 24-h AHI <10 events/h.
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PG was calculated as the ratio between the variances of





The PG repeatability was assessed in 5 volunteers on 2
consecutive days.
Statistical Analysis
Statistical analysis was performed using SPSS (IBM Statistics,
version 25.0; 2017). A 2-tailed P<0.05 was considered
significant. Values were expressed as meanSD or median
and interquartile range, according to a normal or skewed
distribution, evaluated by Kolmogorov-Smirnov test; or as
percentages for categorical data. The v2 goodness-of-fit test
for modified hyperbolic function was used to verify the shape
of the PG relationship, using GraphPad Prism, version 7.04 for
Windows.
For quantitative variables, comparison between 2
groups was performed using Mann-Whitney U test, whereas
comparison among >2 groups was performed using the
Kruskal-Wallis test, with Dunn post hoc correction. For
qualitative variables, a v2 or Fisher exact test was used.
Before regression analysis, variables with a skewed
distribution were logarithmically corrected. Univariable and
multivariable linear regression analyses were implemented to
identify predictors of CSR severity and CSR cycle length
(dependent variables), entering the CG, the PG, and the LFCt
(independent variables) into the multivariable regression only
if they resulted in predictors at univariable analysis with
P≤0.05; multicollinearity was excluded by calculation of
variance inflation factor, considering a low risk of multi-
collinearity if the variance inflation factor was <10. Repeata-
bility was measured with the intraclass correlation coefficient
and its 95% confidence interval.
Results
The clinical characteristics of the HF population are shown in
Table 1. Patients were mainly men, with mild symptoms (90%
in New York Heart Association class I/II) confirming clinical
stability, despite moderate-severe left ventricular systolic and
diastolic dysfunction and presence of relevant mitral regur-
gitation and atrial fibrillation in 50% and 40%, respectively. All
patients were receiving optimal medical and device treatment.
According to matching criteria, patients and healthy controls
were similar ages (72.46.4 versus 69.22.7 years; P=0.14),
had a similar proportion of men (95% versus 90%; P=0.28),
and had a similar body mass index (26.33.3 versus
25.93.7 kg/m2; P=0.76) and body surface area
(1.970.17 versus 1.900.18 m2; P=0.10).
Patients with CSR showed a higher plasma value of NT-
proBNP (N-terminal pro-B-type natriuretic peptide; P=0.03)
compared with patients without CSR (Table 1). No differences
Table 2. Respiratory Profile of Patients With HF With or Without CSR
Variable Patients With HF Patients With HF With 24-h AHI <10 events/h Patients With HF With 24-h AHI ≥10 events/h
Daytime AHI, events/h 5 (2.0–14.5) 2 (0.8–5.3) 13 (4.8–27.0)*
Nighttime AHI, events/h 18 (5–31) 5 (2.8–11.8) 31 (22.8–36.8)*
24-h AHI, events/h 9 (4.3–17.8) 4.5 (2.8–7.0) 19.5 (15.8–31.3)*
Daytime CAI, events/h 0 (0–3) 0 (0–0) 3 (1.8–18.8)*
Nighttime CAI, events/h 2.5 (0–14.5) 0 (0–1) 14 (7.0–21.3)*
24-h CAI, events/h 1.5 (0–8) 0 (0–0) 7.5 (3.8–17.3)*
Daytime OAI, events/h 0 0 0 (0–1)
Nighttime OAI, events/h 1 (0–2) 0 (0–2) 2 (0.8–2.5)
24-h OAI, events/h 0.5 (0–1) 0 (0–1) 1 (0–1.3)
Cycle length, s 59.810.7 53.17.7 66.59.1*
Apnea length, s 20.33.8 17.42.9 23.21.8*
Hyperpnea length, s 39.67.9 35.86.2 43.47.8*
SaO2 min, % 86.13.3 86.73.8 85.52.7
T-90, min 5 (2–12) 4 (0.8–11) 9 (2–13)*
Data are given as median (interquartile range) or meanSD. AHI indicates apnea-hypopnea index; CAI, central apnea index; CSR, Cheyne-Stokes respiration; HF, heart failure; OAI,
obstructive apnea index; SaO2, oxygen saturation; T-90, time spent with SaO2 <90%.
*P<0.05 vs patients with HF with 24-h AHI <10 events/h.
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in age, body mass index, body surface area, New York Heart
Association class, renal function, left ventricular systolic and
diastolic function, systolic pulmonary pressure, and right
ventricular function were observed between patients with or
without CSR (Table 1).
Because of patient allocation, patients with CSR showed
increased AHI and CAI at daytime, nighttime, and over 24
hours, as well as increased CSR cycle length, apnea and
hyperpnea length, and time spent with SaO2 <90%, whereas
no difference was found in the obstructive apnea index
(Table 2).
Chemoreflex Sensitivity, PG, and Ct
Patients with CSR showed higher CGCO2 compared with both
patients without CSR (P=0.02) and healthy controls (P=0.01,




Patients With HF With 24-h AHI <10 events/h
(n=10)
Patients With HF With 24-h AHI ≥10 events/h
(n=10)
CG
Baseline VE, L/min 11.92.0 11.92.4 11.32.4
Baseline etCO2, mm Hg 33.63.4 31.93.2 31.83.4
Baseline SaO2, % 95.71.1 95.91.6 95.41.5
CGO2 etCO2, mm Hg 32.55.7 31.53.1 31.43.5
CGO2 SaO2, % 78.21.4 81.54.8 81.64.7
CGO2 VE, L/min 19.68.0 17.65.1 22.67.7
CGO2 , L/min per %SaO2 0.19 (0.06–0.69) 0.29 (0.14–0.60) 0.42 (0.23–0.67)
CGCO2 etCO2, mm Hg 47.34.6 47.53.1 48.03.6
CGCO2 SaO2, % 95.81.2 95.51.4 96.31.2
CGCO2 VE, L/min 24.19.1 26.25.4 36.111.1†
CGCO2 , L/min per mm Hg 0.82 (0.15–1.13) 0.89 (0.48–1.01) 1.45 (0.99–2.26)*
†
PG
Baseline VE, L/min 11.92.0 11.92.4 11.32.4
10% VE, L/min 10.33.9 10.62.2 9.92.2
20% VE, L/min 9.52.0 9.82.4 8.61.8
20% VE, L/min 14.22.0 14.73.1 13.92.4
40% VE, L/min 17.32.3 17.33.2 16.22.1
60% VE, L/min 20.32.6 19.93.7 18.92.9
Baseline etCO2, mm Hg 33.83.5 31.43.4 32.23.1
10% etCO2, mm Hg 34.23.3 32.73.2 33.72.9
20% etCO2, mm Hg 35.23.4 32.83.0 35.33.2
20% etCO2, mm Hg 29.73.3 28.13.1 27.93.6
40% etCO2, mm Hg 26.63.4 25.22.5 24.52.3
60% etCO2, mm Hg 24.23.1 22.32.5 20.92.4†
PG, mm Hg/L per min 1.15 (0.83–2.06) 1.37 (1.09–1.88) 2.19 (1.44–2.81)*†
Ct
Daytime LFCt, s  26.72.8 33.46.9‡
Nighttime LFCt, s  26.13.1 32.96.4*
24-h LFCt, s  26.43.6 34.06.2‡
Data are given as meanSD or median (interquartile range).CGO2 and CGCO2 etCO2, SaO2, and VE are the values recorded and averaged in the last 10 seconds of the CGO2 and CGCO2
maneuvers. AHI indicates apnea-hypopnea index; CG, chemoreflex gain; CGCO2 , CG to hypercapnia; CGO2 , CG to hypoxia; Ct, circulation time; etCO2, end-tidal CO2; HF, heart failure; LFCt,
lung-to-finger Ct; PG, plant gain; SaO2, oxygen saturation; VE, minute ventilation.
*P<0.05 vs HF with 24-hour AHI <10 events/h.
†P<0.05 vs healthy controls.
‡P<0.01 vs HF with 24-hour AHI <10 events/h.
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Table 3 and Figure 2). Conversely, no difference was found in
CGO2 among the different groups (Table 3 and Figure 3). No
difference in both CGO2 and CGCO2 was found between
patients without CSR and healthy controls.
Both healthy subjects and patients with HF were able to
perform the PG test correctly (Table 3), with little deviation
from target ventilation (3.11.4% in the whole population,
2.72.9% in healthy subjects, 2.91.4% in those with HF
without CSR, and 3.61.1% in those with HF with CSR). The
PG test showed a high repeatability: intraclass correlation
coefficient, 0.98 (95% CI, 0.91–0.99). The best-fitting curve to
express the relationship between induced changes in etCO2
and changes in ventilation was a hyperbola (R2=0.99 for
patients without CSR and healthy controls, and R2=0.98 for
patients with CSR) (Figure 4A).
PG was higher in patients with CSR than in patients without
CSR (P=0.02) and healthy controls (P=0.01, Table 3 and
Figure 4B). No difference in PG was found between patients
without CSR and healthy controls. No significant difference in
spirometry, lung diffusion, and blood gas analysis was found
between patients with normal and increased PG, apart from a
trend toward an increase in the forced expiratory volume in the
first second (P=0.06) and in the total lung capacity (%
predicted; P=0.09) in patients with increased PG (Table 4).
The 24-hour, daytime, and nighttime LFCt values were all
increased in patients with CSR compared with patients
without CSR (all P<0.05, Figure 5). No significant differences
were observed in the LFCt calculated at different time
windows (daytime, nighttime, and 24-hour period), within the
same group of patients.
CGCO2 and LFCt were correlated (q=0.64, P=0.004),
whereas no correlation was found between PG and CGCO2 or
PG and LFCt.
Prediction of CSR Severity and CSR Cycle Length
The univariable and multivariable predictors of CSR severity in
patients with HF are shown in Table 5, whereas linear
regression plots (for each CSR predictor) are shown in
Figure 6.
At multivariable analysis, CGCO2 and PG were independent
predictors of both the 24-hour AHI (Figure 7A) and the












































Figure 2. Chemoreflex gain to hypercapnia in healthy
subjects and in patients with and without Cheyne-Stokes
respiration (CSR). A, Linear regression slopes expressing
the chemoreflex gain to hypercapnia (CGCO2 ) in a sample
subject of each study group. B, CGCO2 was increased in a
patient with heart failure (HF) with CSR compared with
patients with HF without CSR and healthy subjects. AHI











































Figure 3. Chemoreflex gain to hypoxia in healthy sub-
jects and in patients with and without Cheyne-Stokes
respiration (CSR). A, Linear regression slopes expressing
the chemoreflex gain to hypoxia (CGO2 ) in a sample subject
of each study group. B, No difference was found among
healthy subjects and patients with heart failure (HF) with or
without CSR in terms of CGO2 . AHI indicates apnea-
hypopnea index; SaO2, oxygen saturation; VE, minute
ventilation.
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independent predictor of the daytime AHI (Figure 7C). LFCt
was only a univariable predictor of nighttime AHI, but it lost
its predictive value at multivariable analysis. Using CAI as
the target variable, PG was the only predictor of 24-hour
(R=0.55, P=0.01) and daytime (R=0.59, P=0.006) CAI,
whereas CGCO2 was the only predictor of nighttime CAI
(R=0.56, P=0.01).
On the other hand, the LFCt was an independent
predictor of CSR cycle length (Figure 8A), as well as of
hyperventilation length (Figure 8B). Apnea length was pre-
dicted by both LFCt and the CGCO2 , with LFCt remaining the
only independent predictor at multivariable analysis (Fig-
ure 8C).
Discussion
This was the first study to assess the PG in patients with HF
with and without CSR. Assessing the PG, instead of only CG
and the Ct, allowed us to comprehensively test the instability
loop hypothesis (Figure 9).13 Higher CGCO2 , PG, and Ct values
were found in patients with CSR. Notably, both CG and PG
were able to predict CSR severity during the 24-hour period
and at nighttime, whereas only PG was able to predict CSR
severity at daytime. Ct showed no role in CSR severity
prediction, but was strongly related to CSR cycle length and to
hyperpnea and apnea length.
The Instability Loop Hypothesis
The pathophysiological characteristics of CSR in HF are
complex and multifactorial. Despite much theoretical and
experimental work, a thorough understanding of the mecha-
nisms involved and their interactions has not been achieved.
The strength of the pathophysiological model is key to guide
experiments designed to challenge the model’s assumption
and to provide optimal treatments for patients with a
disease.32 On the other hand, if a treatment is not strongly
pathophysiologically based and referred to a solid model, the
randomized controlled trial is likely to fail, as happened to
mask-based therapies based on positive airway pressure,
derived from the treatment of obstructive apneas and applied
to central apneas of HF.7,8
In this setting, a great contribution was provided by the use
of mathematical models. Currently, the most accepted
hypothesis is that the respiratory control system could be
seen as a closed-loop system, constituted by a controller (ie,
the chemoreflex) and the plant (ie, the lung), with a transit
time in the feedback loop (ie, Ct). In principle, therefore,
increased CG, increased PG, and increased Ct have theoret-
ical potential to increase the global LG and cause CSR.
Testing the Instability Loop Hypothesis: CG
Alteration in the gain of the chemoreceptors has been well
documented in both experimental33 and clinical settings.15–19
The original observation by Javaheri15 that CGCO2 was strongly
correlated with CSR severity was later confirmed by different
research groups.16–19,34 In the current study, the CGCO2 was
again confirmed to play a key role in the prediction of CSR
severity. By contrast, no significant difference in the CGO2 was
found between patients with or without CSR, highlighting once
more that CO2, rather than hypoxia, is the main driver of
ventilation, especially at night when ventilation is under
chemical control. Recent lines of evidence have shown that in
animals with HF, the CG remains high throughout the
24 hours, including the biological night, differently from
healthy animals in which the CG is known to decrease during
the inactive phase.35 This may also justify why the difference
between the eupneic CO2 and the CO2 at anaerobic threshold
is decreased at night in patients with HF and CSR compared
with patients with stable breathing.36 The reasons for this
persistent overactivity of the CG at night is still unknown, but
key differences in the chronobiological characteristics of
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Figure 4. Plant gain (PG) in healthy subjects and in
patients with and without Cheyne-Stokes respiration (CSR).
A, PG respiratory hyperbola in a sample subject of each
study group. B, PG was increased in a patient with heart
failure (HF) with CSR compared with patients with HF
without CSR and healthy subjects. AHI indicates apnea-
hypopnea index; etCO2, end-tidal CO2; VE, minute
ventilation.
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(decreased cardiac output and increased filling pressure),
together with a decrease in cerebrovascular reactivity to
increased CO2 (decreased CO2 washout from chemorecep-
tors),37 at night might be involved.
Testing the Instability Loop Hypothesis: PG
Before this study, the PG had been only mathematically
hypothesized9–12 and evaluated in a single study by Miyamoto
et al in healthy volunteers,38 but not in patients with HF.
Similar to Miyamoto et al, we also used a visual system to
drive subjects during PG execution, but we performed shorter
ventilatory maneuvers, to increase the feasibility in patients
with HF. Moreover, we calculated the PG as a ratio between
the variances of etCO2 and ventilation, rather than using a
linear slope obtained at the equilibrium set point,38 to
more reliably express the PG behavior far from stationary
conditions.
The feasibility of the test was demonstrated by the
reassuringly small discrepancy (<5%) between the target
and recorded ventilation in each respiratory maneuver, not
only in healthy subjects, but even in patients with HF with or
without CSR. Furthermore, as predicted by mathematical
models, the relationship between changes in ventilation and
the resulting changes in etCO2 fitted a hyperbola (R
2=0.99 for
patients without CSR and healthy controls, and R2=0.98 for
patients with CSR).
Notably, we first observed that the PG is increased in
patients with HF with CSR, being 60% higher than in
patients with HF without CSR. Moreover, the PG was the
only predictor of CSR severity at daytime, where the
chemical control is overdriven by different stimuli, especially
cortical influences. Furthermore, adding PG to CG resulted in
a more accurate prediction of CSR severity at night
(PG+CGCO2 R=0.81 versus CGCO2 alone R=0.61). To put into
practice, this means that in patients with a high PG,
whatever stimulus is able to change ventilation can make
the system oscillate and cause CSR, such as exercise or a
mental stress when the patient is awake or an arousal when
the patient is sleeping. This should be accounted for when
Table 4. Blood Gas Analysis, Spirometry, and Pulmonary Diffusion in Patients With HF With Low or High PG, According to Its
Median Value (1.63 mm Hg/L per Minute)
Variable Patients With HF (n=20) Patients With Low PG (n=10) Patients With High PG (n=10)
Blood gas analysis
PO2, mm Hg 80.88.3 82.07.4 79.99.4
PCO2, mm Hg 36.83.4 37.64.4 36.12.6
pH 7.430.04 7.420.03 7.440.04
HCO3 , mmol/L 25.22.1 24.81.0 25.52.6
SaO2, % 97.71.3 97.61.8 97.91.0
Spirometry
FEV1, L 2.990.48 2.760.35 3.20.50
FEV1, % predicted 106.818.0 99.319.9 113.414.0
FEV1/FVC, % 70.75.6 71.37.6 70.13.4
FEV1/VC, % predicted 92.08.5 92.611.3 91.55.6
TLC, L 6.41.0 6.01.0 6.80.9
TLC, % predicted 97.413.7 90.912.6 103.212.5
RV/TLC, % 33.76.9 36.35.3 31.47.7
DS/TV 0.160.06 0.160.06 0.170.05
Pulmonary diffusion
DLCO, mL/min per mm Hg 23.85.4 22.65.2 24.95.6
DLCO, % predicted 88.527.4 77.332.5 98.618.5
AV, L 6.20.9 5.80.4 6.70.9
AV, % predicted 95.712.6 89.111.4 101.611.0
KCO, mL min1 mm Hg1 L1 3.80.7 3.90.8 3.80.6
KCO, % predicted 99.117.8 101.020.6 97.316.0
Data are given as meanSD. AV indicates alveolar volume; DLCO, diffusion capacity of the lungs for CO; DS, dead space; FEV1, forced expiratory volume in the first second; FVC, forced
VC; HF, heart failure; KCO, DLCO divided by AV; PG, plant gain; SaO2, oxygen saturation; RV, residual volume; TLC, total lung capacity; TV, tidal volume; VC, vital capacity.
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Figure 5. Lung-to-finger circulation time (LFCt) in patients with and without Cheyne-
Stokes respiration (CSR). The LFCt was increased in patients with heart failure (HF) with
Cheyne-Stokes respiration (CSR) compared with patients without CSR, over the 24-hour
period (A), at daytime (B), and at nighttime (C). AHI indicates apnea-hypopnea index.
Table 5. Univariable and Multivariable Models for Prediction of 24-Hour AHI, Nighttime AHI, and Daytime AHI
Variable
Univariable Model Multivariable Model
b, MeanSD R R2 P Value b, MeanSD R R2 R2-Penalized P Value VIF
Prediction of 24-h AHI
CGCO2 6.93.3 0.46 0.21 0.04 8.32.7 0.71 0.51 0.44 0.008 1.03
PG 8.33.1 0.54 0.29 0.02 8.92.9 0.009 1.03
LFCt 0.70.4 0.38 0.14 0.10 
Prediction of nighttime AHI
CGCO2 11.43.7 0.61 0.36 0.007 10.43.3 0.81 0.65 0.57 0.007 1.24
PG 8.54.1 0.44 0.19 0.04 8.13.3 0.03 1.06
LFCt 1.10.5 0.49 0.24 0.03 
Prediction of daytime AHI
CGCO2 3.93.4 0.26 0.07 0.29 
PG 8.32.8 0.56 0.32 0.01
LFCt 0.410.38 0.25 0.06 0.29
AHI indicates apnea-hypopnea index; CGCO2 , chemoreflex gain to hypercapnia; LFCt, lung-to-finger circulation time; PG, plant gain; VIF, variance inflation factor.
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designing and testing novel treatments aimed at stabilizing
breathing.
Indeed, several therapeutic approaches have been thought
to act on the PG to obtain ventilatory stability, such as CO2
administration (by increasing lung CO2 reserve),
39,40 increase
of death space (thus decreasing the washout of CO2 from the
lung),41 acetazolamide administration (causing a shift in the
ventilatory equilibrium at a different set point),42,43 and
positive pressure ventilation (by altering lung anatomical
characteristics and/or mechanics).12 The PG was recently
measured in patients with obstructive sleep apnea (n=8) and
matched controls (n=7), by using a pseudorandom binary
stimulation (63 breaths alternating between room air and 4%
CO2, switching frequencies of between 1 and 6 consecutive
breaths of CO2).
44 No difference was found between patients






























































































































































Figure 6. Linear regression plots relating loop gain components and Cheyne-Stokes respiration (CSR) severity in different time
windows. Linear regression plots relating chemoreflex gain to hypercapnia (CGCO2 ), plant gain (PG), and lung-to-finger (LF)
circulation time (LFCt) with CSR severity, as expressed by the apnea-hypopnea index (AHI), over the 24-hour period (A), at
nighttime (B), and at daytime (C).
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the PG was observed after 6 week of continuous positive
airway pressure treatment.
The main determinants of the PG remained still unknown.
In contrast to the hypothesis that lung congestion and the
gas-diffusion impairment may increase the PG,45 in our
population, no significant difference in spirometry, lung
diffusion, and blood gas analysis parameters was found
between patients with high PG (PG above the median) and low
PG (Table 4). The only exception was a trend toward an
increase in forced expiratory volume in the first second
(P=0.06) and total lung capacity (P=0.09) in patients with high
PG. These results should be interpreted with caution, and
further investigations in a larger population are needed to
address this key pathophysiological issue.
Testing the Instability Loop Hypothesis: Ct
The pathophysiological role of Ct delay in determining
respiratory instability was supposed by mathematical model-
ing9–12 and experimentally demonstrated in dogs by Crowell
and coworkers already in 1956.14 However, the increase in Ct
needed to make ventilation unstable in anesthetized dogs14
was much higher (from 40 seconds to 5 minutes) than that
observed in patients with HF.20 Subsequent studies in
humans have highlighted that Ct delay seems to be mainly
associated with CSR cycle length and hyperventilation length,
rather than CSR onset or severity.20
In our population and differently from previous studies, the
LFCt, besides cycle length and hyperpnea length, also






















































Figure 7. Regression plots showing predictors of Cheyne-Stokes respiration severity in different time windows. Chemoreflex gain to
hypercapnia (CGCO2 ) and plant gain (PG) were independent predictors of apnea-hypopnea index (AHI) over the 24-hour period (A) and at











































Figure 8. Regression plots showing predictors of Cheyne-Stokes respiration (CSR) cycle and hyperpnea and apnea
lengths. The lung-to-finger circulation time (LFCt) was the only independent predictor of CSR cycle length (A),
hyperventilation length (B), and apnea length (C).
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explained by the use of LFCt over the 24-hour period in place
of the lung-to-ear Ct, evaluated only in phase 2 non–rapid eye
movement sleep in the article by Hall et al,20 or by the higher
number of patients with HF recruited in the current study.
Both methods (LFCt and lung-to-ear Ct) were inversely
correlated with cardiac output.20,28,29
Study Limitations
The PG test requires patient cooperation, and so it is
unsuitable when there is marked physical and/or cognitive
impairment. Nonetheless, in our population, the feasibility was
100%, even in patients with unstable breathing. Although the
LFCt is only an estimation of the true Ct, it has the advantage
of being measurable directly from cardiorespiratory monitor-
ing. However, being based on SaO2, LFCt may also be
influenced by the lungs and hemoglobin levels, so that direct
measurements of Ct are needed to further improve the
precision of the model.
The CG and the PG were only evaluated during the daytime,
when the patient was awake, and this may decrease our
capacity to predict the ventilatory behavior (stability/insta-
bility and CSR severity and length) throughout the 24 hours.
Currently, there is no evidence in patients with HF about the
potential changes in the CG and the PG from awake to sleep
conditions. Although we can hypothesize that the CG would
remain high at night in patients with unstable breathing, as
observed in animals,35 the potential changes of the PG at
night are less predictable. We believe that, at night, the
change in body position may reduce lung volumes, and further
potential influences on the PG may be also related to the
typical rostral fluid shift of patients with HF.
Finally, the relatively small sample size of the study seems
to hardly support the development of multivariable models.
However, having used only 3 variables (independent variables;
namely, the CG, the PG, and the LFCt) with a strong
pathophysiological relationship with CSR severity and length
(dependent variables), together with the lack of any relation-
ships between the independent variables, apart from that
observed between CGCO2 and LFCt, has actually increased the
power of analysis (in each multivariable regression model, the
calculated power was always >98%). Furthermore, the
variance inflation factor observed makes the risk of multi-
collinearity rather low.
Conclusions and Perspectives
Ct does not predict CSR severity, but it influences the CSR
cycle and hyperpnea and apnea length. The PG can be easily
measured in patients with HF and is increased in patients with
HF presenting with unstable ventilation, as previously hypoth-
esized by mathematical models. Its estimation may help in
predicting the severity of CSR at daytime and in refining the
prediction of CSR severity at nighttime, when evaluated
together with the CG. Future treatment strategies should
consider those triggers to tailor a rational and thus effective
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